| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Small Molecules | Dermatologic System | ||
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Small Molecules | Dermatologic System | ||
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Small Molecules | Dermatologic System |
Recent Updates
Recently added Catalysts
Roivant Sciences Ltd.$33.95
-0.94 (-2.69%)
B 60Pipeline Score Overvalued Biotech · Clinical
Market Cap
21.55 B
EPS
-0.45
P/E Ratio
-
Value Trade
103.41 M
SEC Financials
Q1 2026Dilution Risk
Revenue
2.52 M
R&D Expenses
198.94 M
Operating CF
-187.59 M
Total Assets
5.71 B
Total Liabilities
416.27 M
Equity
4.53 B
D/E Ratio
12,345
2.46 %
Week
1.46 %
1 Month
9.62 %
3 Month
47.88 %
6 Month
204.16 %
5 Year
185.33 %
All Time
Cash Data
Cash Position
4.29 B
Monthly Burn
62.53 M
Runway
66.9 mo
Burn Trend
SEC Filing
May 20, 2026
Overview
Volume
1.57 M
52 Week Range
10.59 - 32.79
% held by Insiders
28.04 %
% held by Institutions
73.15 %
Enterprise Value
18.13 B
Total Shares
716.25 M
Short %
6.42 %
Float Shares
371.02 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Roivant Sciences Ltd.
267Total events
7Upcoming
105Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 2
TBD
T2Product Launch
Subscribe to view catalyst details
TBD
T1Topline Readout
Subscribe to view catalyst details
Event history 2
TBD
▲Milestone PaymentCorporate
Subscribe to view catalyst details
TBD
◆PDUFA DateBrepocitinibFiledRegulatory Filing
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-06-17 | brepocitinib | Phase 3 data readout | Phase 3 | — | – | – | – |
2025-06-17 | brepocitinib | Phase 3 data readout | Phase 3 | — | – | – | – |
2025-06-17 | brepocitinib | Phase 3 data readout | Phase 3 | — | – | – | – |
Drug Pipeline Intelligence
B60
Pipeline Score $4.0B
Pipeline ValueOvervalued
Valuation Signal6
Drugs Scored0.2x
rNPV / MCap Top 87%
Mid Cap (rank 120 of 912)
Percentile RankRoivant Sciences Ltd. holds a solid B-grade pipeline (60/100), with $4.7B risk-adjusted pipeline value, led by Brepocitinib in Cutaneous Sarcoidosis (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brepocitinib Small molecule | Dermatomyositis | Phase 3 | NCT05437263 | 88% | $1.3B | ACTIVE NOT_RECRUITING | 246 | SLOW | B (72) | Jul 1, 2026 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
brepocitinib BreakthroughPriority | dermatomyositis | Phase 3 | 2026-03-30 | 15.3-point greater improvement in mean Total Improvement Score (TIS) at Week 52 compared to placebo (P<0.001); nearly twice as many patients reducing background corticosteroids in the brepocitinib 30 mg group compared to placebo Read More | New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis Read More | |
brepocitinib BreakthroughPriority | dermatomyositis | Phase 3 | 2026-03-30 | 15.3-point greater improvement in mean Total Improvement Score (TIS) at Week 52 compared to placebo (P<0.001); nearly twice as many patients reducing background corticosteroids in the brepocitinib 30 mg group compared to placebo Read More | New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis Read More | |
brepocitinib BreakthroughPriority | dermatomyositis | Phase 3 | 2026-03-30 | 15.3-point greater improvement in mean Total Improvement Score (TIS) at Week 52 compared to placebo (P<0.001); nearly twice as many patients reducing background corticosteroids in the brepocitinib 30 mg group compared to placebo Read More | New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ROIV
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ROIV Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2028-01-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2028-01-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2028-01-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ROIV▲ +14.9%on this news
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
Roivant reported its financial results for the fourth quarter and fiscal year ended March 31, 2026, highlighting promising clinical data for IMVT-1402 in rheumatoid arthritis and brepocitinib's Breakthrough Therapy Designation for cutaneous sarcoidosis. The company anticipates a commercial launch of brepocitinib in dermatomyositis by September 2026 and has a robust cash position of $4.3 billion. However, R&D expenses have increased significantly, reflecting ongoing investments in their pipeline.
Read more →ROIVRoivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026
Roivant has announced a live conference call scheduled for May 20, 2026, to report its financial results for the fourth quarter and fiscal year ending March 31, 2026. The call will also provide a business update. Roivant's pipeline includes several innovative therapies targeting various autoimmune conditions and pulmonary hypertension.
Read more →ROIVPriovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
Priovant has launched a new Phase 2b/3 clinical trial for brepocitinib targeting lichen planopilaris (LPP), a severe inflammatory scalp disorder. This trial marks the fourth indication for brepocitinib, which has shown promising results in previous studies. The FDA has granted Priority Review for brepocitinib's NDA for dermatomyositis, with further developments expected in other indications.
Read more →ROIVRoivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
Roivant has launched a new Phase 2b/3 trial for brepocitinib targeting lichen planopilaris (LPP), a severe inflammatory scalp disorder. This marks the fourth indication for brepocitinib, which has shown promising results in prior studies. Meanwhile, Immunovant reported that its Phase 3 studies for batoclimab in thyroid eye disease did not meet their primary endpoint. An investor call is scheduled to discuss these developments.
Read more →ROIVNew England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
Priovant Therapeutics announced positive results from the Phase 3 VALOR trial of brepocitinib for dermatomyositis, published in the New England Journal of Medicine. The trial met its primary endpoint, showing significant improvement in Total Improvement Score and enabling corticosteroid reduction. Despite some increased serious infections, the findings suggest a potential shift in treatment paradigms for dermatomyositis.
Read more →ROIVPriovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis
Priovant Therapeutics announced that the FDA has accepted its New Drug Application for brepocitinib, a potential treatment for dermatomyositis, and granted it Priority Review. The application is supported by positive results from the Phase 3 VALOR study, which showed significant improvements in patient outcomes. If approved, brepocitinib would be the first targeted therapy for this condition, with a launch anticipated by September 2026.
Read more →ROIVRoivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorabl
Roivant announced a $2.25 billion global settlement between Genevant Sciences and Arbutus Biopharma with Moderna. The agreement resolves patent infringement claims over LNP delivery technology used in Moderna's COVID-19 vaccines. Moderna will pay $950 million upfront and an additional contingent payment of $1.3 billion based on legal outcomes. This settlement supports Genevant's ongoing litigation efforts and validates their intellectual property, enhancing financial stability for future investments.
Read more →ROIV▲ +22.1%on this news
Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025
Roivant announced positive Phase 2 results for brepocitinib in cutaneous sarcoidosis, marking a significant milestone in treatment options for this condition. The BEACON study demonstrated substantial clinical improvements, particularly in the 45 mg dosage group. The company plans to initiate a pivotal Phase 3 study in 2026, further advancing its pipeline.
Read more →ROIV▲ +22.1%on this news
Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
Priovant Therapeutics announced positive Phase 2 results for brepocitinib in treating cutaneous sarcoidosis, marking a significant advancement in a field lacking approved therapies. The BEACON study demonstrated meaningful clinical improvements in patients compared to placebo, with high response rates and a favorable safety profile. The company plans to initiate a Phase 3 program in 2026.
Read more →ROIVRoivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
Roivant has announced a live conference call scheduled for February 6, 2026, to discuss its financial results for the second quarter ended December 31, 2026, along with a business update. The company is focused on advancing its pipeline of therapies, including treatments for autoimmune conditions and pulmonary hypertension. The call will be accessible via phone and webcast, with archived details available on their website.
Read more →ROIV▲ +5.4%on this news
Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day
Roivant hosted an Investor Day in New York City, highlighting its pipeline progress and strategic outlook. CEO Matt Gline emphasized the potential of three major products, including brepocitinib for dermatomyositis, which is set for a Phase 3 readout. The company aims for significant commercial launches in the coming years.
Read more →ROIVRoivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update
Roivant reported its financial results for Q2 2025, highlighting a cash position of $4.4 billion. The company noted transformative data from brepocitinib and promising results from Immunovant in Graves' disease. However, it also reported a loss from continuing operations of $166 million, reflecting increased R&D expenses. Roivant plans to provide further updates at an investor day in December.
Read more →ROIVRoivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
Roivant (Nasdaq: ROIV) is set to report its financial results for the second quarter ended September 30, 2025, in a live conference call on November 10, 2025. The call will also include a comprehensive business update, reflecting Roivant's ongoing commitment to maintain transparency with its investors. The company continues to advance its pipeline of innovative therapies targeting several significant health conditions. Notably, Roivant operates multiple subsidiaries designed to expedite the development and commercialization of critical medicines.
Read more →ROIV▲ +7.8%on this news
Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)
Roivant and Priovant Therapeutics announced positive results from the Phase 3 VALOR study of brepocitinib for dermatomyositis. The study demonstrated significant improvements in the primary endpoint, with brepocitinib showing a mean Total Improvement Score of 46.5 compared to 31.2 for placebo. This marks a groundbreaking achievement in the treatment of dermatomyositis, with plans for an NDA submission in 2026.
Read more →ROIVRoivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List
Roivant has been recognized as one of the Best Workplaces in BioPharma by Fortune and Great Place To Work, ranking 28th in the small & medium category. This marks Roivant's first appearance on the list, highlighting its commitment to a positive workplace culture. The selection was based on survey responses from nearly 40,000 employees across the biotechnology and pharmaceutical sectors.
Read more →ROIVRoivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
Immunovant, Inc. presented promising six-month off-treatment data for batoclimab in uncontrolled Graves' disease patients. The results indicate significant remission rates and potential disease modification. The findings will be discussed at the upcoming American Thyroid Association meeting, highlighting the drug's transformative potential for treatment if approved by the FDA.
Read more →ROIVRoivant Reports Financial Results for the First Quarter Ended
Roivant reported its financial results for the first quarter ended June 30, 2025, indicating a significant increase in operational losses and expenses. The company completed a $1.5 billion share repurchase program and currently holds a robust cash position of approximately $4.5 billion. Despite high operating losses, Roivant is optimistic about the near-term readout of its DM trial and the potential launch of brepocitinib, aimed at addressing unmet patient needs. Financially, research and development expenses surged due to increased program-related costs and higher personnel expenses.
Read more →ROIVRoivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025
Roivant has announced that it will host a live conference call on August 11, 2025, to report its financial results for the first quarter ended June 30, 2025, and to provide a business update. The company's ongoing efforts include developing a range of treatments for autoimmune diseases and other medical conditions, highlighting their focus on meaningful health innovations. Investors can access the call via registration online and find details in the Investors section of Roivant's website.
Read more →ROIVRoivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis
Roivant and Priovant Therapeutics will host a live investor video conference on June 17 to discuss brepocitinib and its potential impact on dermatomyositis. Brepocitinib, a dual selective inhibitor, aims to address the unmet medical needs of patients suffering from this condition. The conference will provide insights into the drug's clinical development and therapeutic potential.
Read more →ROIV▲ +6.4%on this news
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended
Roivant Sciences reported its financial results for the fourth quarter and fiscal year ended March 31, 2025. The company expressed pride in its development progress, particularly highlighting positive outcomes from its myasthenia gravis study and the expansion of its pipeline. However, Roivant also reported a significant loss from continuing operations and noted increased R&D expenses, which raise concerns about ongoing expenditures and profitability. The company has a cash position of approximately $4.9 billion, allowing for continued investment in its late-stage clinical programs.
Read more →ROIVRoivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025
Roivant announced that it will host a live conference call on May 29, 2025, to report its financial results for the fiscal year ending March 31, 2025, and provide a business update. The company is known for its innovative approach in drug development, with a pipeline that includes treatments for autoimmune disorders and pulmonary hypertension. The details of the conference call will be accessible on Roivant's website, including an archived webcast post-event. This announcement highlights Roivant's continued engagement with investors and stakeholders.
Read more →ROIVImmunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sj gren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 Eric Venker, M.D. (
Immunovant has announced a new phase of growth involving leadership changes and the expansion of its IMVT-1402 development into Sjögren's Disease and Cutaneous Lupus Erythematosus. Eric Venker, M.D., previously Roivant's President, has taken over as CEO of Immunovant, succeeding Pete Salzmann, M.D., who retired after a significant tenure. The company aims to ramp up efforts in clinical execution as it progresses with the new indications and aligns more closely with Roivant's strategic vision. These changes come amidst ongoing development challenges and the necessity for innovative treatments in the autoimmune disease sector.
Read more →ROIVRoivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in
Immunovant, Inc. has announced positive topline results from its Phase 3 study of batoclimab for Myasthenia Gravis (MG) and initial findings from a Phase 2b study for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The Phase 3 MG study achieved its primary endpoint, with patients receiving higher doses of batoclimab showing significantly improved MG-ADL scores compared to placebo. In the CIDP study, early data indicated a notable responder rate and improvements across multiple assessments. However, the company has decided not to pursue regulatory approval for batoclimab in these indications at this time, pending results from other ongoing trials.
Read more →ROIVRoivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
Immunovant, Inc. announced it will host an investor webcast on March 19, 2025, at 8:00 AM ET. The event will focus on results from the Phase 3 study of batoclimab for Myasthenia Gravis and the initial findings from the Phase 2b study for Chronic Inflammatory Demyelinating Polyneuropathy. Roivant's CEO, Matt Gline, will join Immunovant's CEO, Pete Salzmann, for the discussion. The webcast will be available live on Roivant's website and will be archived for later access.
Read more →ROIVRoivant Reports Financial Results for the Third Quarter Ended
Roivant reported its financial results for Q3 ending December 31, 2024, and announced growth in its clinical pipeline, particularly with the trial of brepocitinib for cutaneous sarcoidosis. The CEO highlighted 2025 as a promising year, anticipating key study outcomes for several treatments. However, the firm faced significant losses from continuing operations and had to discontinue the development of namilumab after a failed Phase 2 trial. Cash reserves remain strong at approximately $5.2 billion, indicating financial stability for ongoing and future projects.
Read more →ROIVRoivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025
Roivant has announced it will host a live conference call on February 10, 2025, to report its financial results for the third quarter ending December 31, 2024. During this call, the company will also provide a business update regarding its ongoing projects and future direction. The announcement highlights Roivant's commitment to transparency and engagement with investors.
Read more →ROIVRoivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis Namilumab failed to show treatment benefit in patients with pulmonary sarcoidosis Further development
Roivant's Kinevant Sciences announced that its Phase 2 RESOLVE-Lung study of namilumab for chronic active pulmonary sarcoidosis did not meet its primary endpoint, showing no treatment benefit. As a result, the company will halt further development of the drug for this indication. Despite the disappointment, Kinevant highlighted the study's contributions to understanding sarcoidosis, committing to publish the results for future research. The safety profile of namilumab remained similar to prior studies, suggesting no new safety concerns were identified in the trial.
Read more →ROIVRoivant Reports Financial Results for the Second Quarter Ended
Roivant Sciences reported its financial results for the second quarter ended September 30, 2024, highlighting continued clinical progress across several programs. Notable advancements include positive data from the Phase 2 study of brepocitinib and successful FDA IND clearance for multiple indications. However, the company also faced significant increases in operating expenses and reported a net loss of $236.8 million. Looking ahead, Roivant anticipates major data releases in 2025 from its various product candidates.
Read more →ROIVRoivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
Roivant has announced a conference call scheduled for November 12, 2024, to discuss its financial results for Q2 2024 and to provide a business update. The company focuses on developing and commercializing medicines that improve patient lives, with a pipeline that includes several therapeutic candidates. Additionally, Roivant operates nimble subsidiaries to advance its biotech initiatives and also supports health technology startups. Details about the call and subsequent archived webcast will be available on their investors page.
Read more →ROIVOrganon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA (tapinarof) Cream, 1% The acquisition expands Organon's dermatology capabilities with a nonbiologic, non-steroidal topical trea
Organon has successfully completed the acquisition of Dermavant Sciences Ltd., broadening its capabilities in dermatology with VTAMA (tapinarof) cream, a novel non-steroidal topical treatment for plaque psoriasis. VTAMA is already FDA-approved and is also being considered for atopic dermatitis, with a PDUFA action date in the fourth quarter of 2024. The acquisition aligns with Organon's commitment to improving women's health and offers promising therapeutic options for patients suffering from chronic skin conditions.
Read more →ROIVOrganon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA (tapinarof) Cream, 1% VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is un
Organon has announced its acquisition of Dermavant Sciences, which includes the innovative dermatologic therapy VTAMA cream for plaque psoriasis. VTAMA, a non-steroidal topical treatment, has been approved by the FDA and is under review for atopic dermatitis. The acquisition is poised to enhance Organon's presence in dermatology, with significant financial implications, including an upfront payment and potential milestone payments. The deal is expected to close in the fourth quarter of 2024, subject to regulatory approvals.
Read more →ROIVRoivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator Mosliciguat, a potential first-in-class and best-in-category
Roivant has announced its new pipeline program, mosliciguat, an inhaled soluble guanylate cyclase activator designed to treat pulmonary hypertension. The proof-of-concept Phase 1b ATMOS study has shown positive data, with notable reductions in pulmonary vascular resistance. Mosliciguat's unique mode of action may provide significant benefits, particularly for patients with pulmonary hypertension-associated interstitial lung disease, who lack effective treatment options. Roivant plans to advance mosliciguat into its Phase 2 PHocus study imminently, aiming to address a substantial market need.
Read more →ROIVRoivant Provides Update on Graves' Disease Development Program High dose batoclimab achieved 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12 High dose batoclimab achieved 56% ATD-free re
Roivant provided a positive update on its Graves' Disease development program, highlighting successful results from a Phase 2a trial of batoclimab. The trial showed a 76% response rate after 12 weeks of treatment, with 56% of patients achieving an ATD-Free Response. Immunovant has also aligned with the FDA for a pivotal trial of IMVT-1402, expected to begin by the end of 2024. This progress underscores Immunovant's commitment to addressing unmet medical needs in patients intolerant or uncontrolled on antithyroid drugs.
Read more →ROIVRoivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024
Roivant announced that it will host a conference call on August 8, 2024, to report its financial results for the first quarter ending June 30, 2024, and to provide a business update. The company is known for its innovative pipeline, which includes several promising drug candidates for autoimmune indications and dermatological conditions. The details of the call, including a registration link, are available on Roivant's website. This event reflects Roivant's ongoing commitment to transparency and communication with investors.
Read more →ROIVRoivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
Roivant has announced a conference call scheduled for May 30, 2024, to discuss its financial results for the fourth quarter and the fiscal year ended March 31, 2024. During this call, the company will also provide a business update, highlighting its progress and future strategies. Roivant's pipeline features several promising biopharmaceuticals, including treatments for autoimmune diseases. Investors can access the call and additional information through the company's website.
Read more →ROIVRoivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Mill
Roivant has announced positive results from the NEPTUNE study, demonstrating significant efficacy of brepocitinib in treating non-anterior non-infectious uveitis. The data show better treatment outcomes compared to existing therapies, positioning brepocitinib as a potential transformative oral therapy. Concurrently, Roivant's board authorized a $1.5 billion share repurchase program, including buying back all shares held by Sumitomo Pharma, reducing shares outstanding by approximately 9%. The program is set to enhance shareholder value, despite market-dependent uncertainties.
Read more →ROIVRoivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024
Roivant has announced plans to host a live conference call on February 13, 2024, to discuss its financial results for Q3 2023 and provide a business update. The event will be accessible online, with archived details available on Roivant's website. In the context of its operations, Roivant is focused on developing innovative therapies, including treatments for autoimmune conditions and psoriasis. However, the company acknowledges inherent uncertainties in achieving its goals amid industry competition.
Read more →ROIV▼ -7.8%on this news
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease
Roivant has announced positive initial results from a Phase 2 clinical trial assessing batoclimab for Graves' disease. The trial, which features a cohort of hyperthyroid patients resistant to anti-thyroid medication, achieved response rates above 50%, with notable IgG reductions of up to 87%. Batoclimab appears to be well-tolerated with no new safety concerns identified. This promising data might position batoclimab as a viable option in treating Graves' disease, addressing a significant unmet need.
Read more →ROIVRoche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease BASEL, Switzerland and LONDON and
Roche has successfully completed its $7.1 billion acquisition of Telavant, which includes rights to the antibody RVT-3101, a potential treatment for inflammatory bowel diseases. Roivant held a majority share in Telavant prior to the acquisition and is optimistic about Roche's plans to further develop RVT-3101. While the acquisition is seen positively due to the promising nature of RVT-3101, there are acknowledged risks associated with potential costs and the impact on business relationships during the transition.
Read more →ROIVRoivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential Results from the 600 mg MAD cohort for IMVT-1402 similar to previously disclosed results from the 300 mg MAD cohort for
Roivant Pharma has reported promising initial results from a Phase 1 clinical trial for IMVT-1402, a treatment aimed at autoimmune diseases. The 600 mg multiple ascending dose cohort demonstrated significant IgG reduction comparable to batoclimab, with a low incidence of adverse events. The findings support the potential of IMVT-1402 as a best-in-class anti-FcRn inhibitor. This development is anticipated to enhance Roivant’s pipeline with a focus on autoregulation and patient self-administration capabilities.
Read more →ROIVRoivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus Oral brepocitinib failed to meet its primary endpoint of Systemic Lupus Erythematosus Responder Index (SRI-4)
Roivant and Priovant announced that oral brepocitinib did not meet its primary endpoint in a Phase 2 study for systemic lupus erythematosus (SLE). Although the study reported high responder rates in the active treatment arm, the notably high placebo response hindered the evaluation of the drug's efficacy. As a result, the companies will not further advance this program in SLE, but they are optimistic about brepocitinib's potential in non-infectious uveitis and dermatomyositis with upcoming studies planned. The overall safety profile of the drug remains favorable, as highlighted by the leadership.
Read more →ROIVRoivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update
Roivant has reported significant financial results for the second quarter ending September 30, 2023, highlighted by a $7.1 billion agreement with Roche for the sale of Telavant. The company also announced promising results from its IMVT-1402 trials, indicating its potential as a leading candidate in autoimmune treatment. Additionally, Roivant shared that VTAMA cream generated $18.4 million in net product revenue, reflecting strong market uptake. The company's financial position remains robust with approximately $1.4 billion in cash and potential future proceeds boosting this further.
Read more →ROIVRoivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors
Roivant has appointed Mayukh Sukhatme, M.D., to its Board of Directors, effective immediately, increasing the board to eight members. Dr. Sukhatme has been with Roivant since its inception and has played a crucial role in guiding the company’s pipeline, which includes various FDA-approved therapies. His new position is expected to bolster Roivant's strategic leadership, as he continues to oversee the development and commercialization of key therapeutic programs.
Read more →ROIVRoivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023
Roivant announced it will hold a financial results conference call on November 13, 2023, to discuss its second-quarter results ended September 30, 2023. The call will provide a business update and include access via registration. Roivant is focused on developing medicines that matter, with a pipeline that includes drugs for autoimmune diseases, showcasing the company’s forward-thinking approach in the biopharmaceutical sector.
Read more →ROIV▼ -11%on this news
Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant Roche will gain the rights to develop,
Roche has entered into a definitive agreement to acquire Telavant Holdings, gaining rights to RVT-3101, a novel TL1A directed antibody for inflammatory bowel disease. This acquisition, valued at $7.1 billion, includes exclusive development rights in the US and Japan. RVT-3101 has shown promising results in clinical trials, potentially benefiting millions suffering from conditions like ulcerative colitis and Crohn's disease. Roche plans to commence a global Phase 3 trial to expedite the therapy's availability.
Read more →ROIV▲ +21.5%on this news
Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
Immunovant, Inc. announced positive early results from the Phase 1 clinical trial of IMVT-1402, which demonstrated significant reductions in Immunoglobulin G (IgG) levels without notable increases in adverse side effects. The trial's data suggested IMVT-1402's potential as a leading treatment for IgG-mediated autoimmune diseases. The company plans to continue releasing further data from the multiple-ascending dose (MAD) cohort, with additional results expected in November. While initial findings are promising, uncertainties remain regarding future clinical trial results and regulatory approvals.
Read more →ROIV▲ +21.5%on this news
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results IMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously obser
Immunovant, Inc. announced positive results from its Phase 1 trial of IMVT-1402, a subcutaneously administered anti-FcRn antibody. The initial data showed dose-dependent reductions in Immunoglobulin G (IgG) levels with favorable safety outcomes, indicating the potential of IMVT-1402 as a leading treatment for IgG-mediated autoimmune diseases. The study revealed a 63% mean reduction in IgG with mild to moderate adverse events, with dosing for higher cohorts underway. Results from the additional cohorts are anticipated in the coming months.
Read more →ROIV▼ -8.7%on this news
Roivant Announces Completion of Redemption of its Outstanding Warrants BASEL, Switzerland and LONDON and
Roivant has successfully completed the redemption of its outstanding public and private placement warrants, which mostly have been exercised. This action saw approximately 98% of the public warrants being executed, leading to the cessation of their trading on Nasdaq. The company remains focused on developing a pipeline of therapeutics aimed at treating several diseases, including psoriasis and autoimmune conditions. The Common Shares will continue to trade under the symbol ROIV.
Read more →ROIVRoivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants BASEL, Switzerland and LONDON and
Roivant has announced the Redemption Fair Market Value for the redemption of its outstanding public and private placement Warrants. The warrants will be redeemed at a price of $0.10 each, and holders must exercise or forfeit their rights by the Redemption Date of September 1, 2023. The Public Warrants will cease trading on Nasdaq the same day. Shareholders will have the option to exercise their Warrants in cash or on a cashless basis, receiving shares in return. Roivant's broader portfolio includes treatments for various autoimmune conditions.
Read more →ROIVRoivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023
Roivant announced a live conference call to discuss its financial results for the quarter ended June 30, 2023, along with a business update scheduled for August 14, 2023. The company, which focuses on biopharmaceutical development, highlighted its diverse pipeline that includes treatments for various autoimmune and inflammatory diseases. The call will be accessible via a registration link, and an archived version of the webcast will be available afterward on their website.
Read more →ROIVRoivant Announces Redemption of Outstanding Warrants BASEL, Switzerland and LONDON and NEW YORK and BOSTON
Roivant has announced the redemption of all outstanding public and private placement warrants, effective September 1, 2023, following a positive share price performance. The company is entitled to redeem these warrants at a price of $0.10 each, as specified in its Warrant Agreement. Holders of the warrants can choose to exercise them for cash or surrender them for shares on a cashless basis. The announcement highlights Roivant's growth as it approaches its established redemption conditions and supports its operational strategy.
Read more →ROIVRoivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program
Roivant, a biopharmaceutical company, has made it to the 25th position on Fast Company’s fifth annual list of the 100 Best Workplaces for Innovators. The company also stands out as the winner in the Science and Technology category, showcasing its commitment to fostering innovation. This recognition highlights Roivant's impressive track record, including 10 positive Phase 3 studies since 2019. The award reflects the company's innovative business model and successful pipeline in inflammation and immunology.
Read more →ROIV▼ -6.3%on this newsshared move
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023
Roivant Sciences has announced a live conference call scheduled for June 28, 2023, to report its financial results for the fourth quarter and fiscal year ending March 31, 2023. Along with the financial update, the company intends to provide additional business insights during the call. The webcast details will be accessible on Roivant's investor relations website, following the live event. This initiative reflects the company's commitment to transparency and engagement with its investors about future business directions.
Read more →ROIVRoivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period This is the first-ever long-duration data rep
Roivant Sciences has reported positive results from the chronic period of the TUSCANY-2 Phase 2b study for RVT-3101, an anti-TL1A antibody for ulcerative colitis. This study demonstrated improved efficacy at 56 weeks compared to the induction period measured at 14 weeks. The results are particularly pronounced in patients with a specific biomarker, which suggests sustained effectiveness across varying doses. These findings bolster RVT-3101's promise as a first-in-class therapeutic option for IBD.
Read more →ROIVRoivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis
Roivant Sciences has announced an investor call scheduled for June 22, 2023, to discuss the results from the chronic period of the TUSCANY-2 Phase 2b study of RVT-3101, a treatment for ulcerative colitis. This study is significant as it involves a global research effort, reflecting Roivant's commitment to addressing healthcare inefficiencies. The investor call will be accessible via phone and webcast, with an archived version available afterward. The announcement highlights Roivant's ongoing research and development in the biopharmaceutical industry.
Read more →ROIVRoivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old - ADORING 1 met the primary and all second
Roivant Sciences announced positive results from its ADORING 1 Phase 3 trial for VTAMA (tapinarof) cream in treating moderate to severe atopic dermatitis in adults and children as young as 2 years old. The trial demonstrated significant improvements across primary and secondary endpoints, including itch reduction and skin clearance rates. With FDA approval anticipated, VTAMA may simplify treatment for various patient age groups and enhance the overall management of atopic dermatitis. The successful results align with findings from a preceding Phase 3 trial, ADORING 2, indicating a strong potential for VTAMA's market introduction.
Read more →ROIV▲ +7.9%on this news
Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old - 46.4% of subjects receiving VTAMA cream,
Roivant Sciences has reported positive topline results from the ADORING 2 Phase 3 trial for VTAMA (tapinarof) cream, showing significant efficacy in treating atopic dermatitis in both adults and children as young as 2 years old. The trial met its primary endpoint with 46.4% of subjects achieving clear or almost clear skin, while also demonstrating significant improvements in itch reduction and overall skin condition. This advancement positions VTAMA as a promising non-steroidal treatment option for atopic dermatitis, pending FDA approval. The company anticipates further data from the ADORING 1 trial in May 2023.
Read more →ROIVRoivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live investor call and webcast at 8:00 AM ET on Wednesday, March 15 to review topline results from the ADORING 2 study, on
Read more →ROIVRoivant Sciences Announces Change to its Board of Directors
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that its founder Vivek Ramaswamy has stepped down from the company’s board of directors to focus on his U.S. presidential campaign. Vivek foun
Read more →ROIVRoivant Sciences Reports Financial Results for the Third Quarter Ended
Roivant Sciences reported its financial results for Q3 2022, highlighting significant operational developments. The company in-licensed the TL1A program RVT-3101 and completed a $230 million equity financing to advance its ulcerative colitis and Crohn's disease programs. While Roivant achieved growth in VTAMA revenue and improved payor coverage, it also reported an increased net loss of $384.9 million. Total research and development expenses decreased, reflecting discontinued programs, yet the company remains optimistic about its market position and upcoming milestones.
Read more →ROIV▼ -11.1%on this news
Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares
Roivant Sciences has announced the pricing of an upsized underwritten public offering of 26,666,666 common shares at $7.50 each. The total gross proceeds from this offering are expected to reach $200 million. The closing is anticipated on February 7, 2023, pending customary conditions. With the addition of a 30-day option for underwriters to purchase up to 3,999,999 more shares, Roivant aims to bolster its financial resources.
Read more →ROIVRoivant Sciences Announces Proposed Public Offering of Common Shares
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) announced today that it has commenced an underwritten public offering of $150 million of common shares. In addition, Roivant expects to grant the underwriters
Read more →ROIVRoivant to Report Financial Results for the Third Quarter Ended December 31, 2022 on Monday, February 13, 2023
Quarterly investor call and webcast scheduled on Monday, February 13 at 8:00 a.m. ET Roivant will also participate in the SVB Securities Global Biopharma Conference in February and the Cowen 43rd Annual Health Care Conference in March BASEL, Switzerland and LONDON and NEW YORK
Read more →ROIV▲ +5.7%on this news· ran to +32% by day 3
Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both
Roivant Sciences announced positive initial results from the TUSCANY-2 Phase 2b study for RVT-3101, an anti-TL1A antibody aimed at treating ulcerative colitis. The study showed statistically significant efficacy across various doses and highlighted a favorable safety profile. Notably, the therapy demonstrated enhanced efficacy in patients who were biomarker positive. Roivant plans to advance RVT-3101 into registrational studies, expecting further data from the chronic therapy period in the first half of 2023.
Read more →ROIV▲ +8.2%on this news
Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases Roivant to develop PF-06480605 (now RVT-3101), a potential first in class, fully human monoclonal
Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases BASEL, Switzerland, LONDON, NEW YORK and BOSTON, December 1, 2022 (GLOBE NEWSWIRE) - Roivant Sciences (Nasdaq: ROIV) and Pfizer Inc. (NYSE: PFE) today announ
Read more →ROIVRoivant Social Ventures Publishes Global Access Scorecard to Guide Impact Investors in Making Equitable Investment Decisions
NEW YORK, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Roivant Social Ventures (RSV), a social impact organization launched by Roivant Sciences, today announced the publication of a proprietary Global Access Scorecard that impact investors can use to guide equitable investment decisions. T
Read more →ROIVRoivant Sciences Reports Financial Results for the Second Quarter Ended
Roivant Sciences Reports Financial Results for the Second Quarter Ended September 30, 2022 and Provides Business Update BASEL, Switzerland, LONDON, NEW YORK and BOSTON, November 14, 2022 - Roivant Sciences Ltd. (Nasdaq: ROIV) today reported its financial results for the second q
Read more →ROIV▼ -11.2%on this news
Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering BASEL, Switzerland, LONDON, NEW YORK, and BOSTON
Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering BASEL, Switzerland, LONDON, NEW YORK, and BOSTON, November 8, 2022 - Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healt
Read more →ROIVRoivant Sciences Announces Proposed Public Equity Offering BASEL, Switzerland, LONDON, NEW YORK, and BOSTON
Roivant Sciences Announces Proposed Public Equity Offering BASEL, Switzerland, LONDON, NEW YORK, and BOSTON, November 7, 2022 - Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, annou
Read more →ROIVRoivant Sciences to Report Financial Results for the Second Quarter Ended September 30, 2022 on Monday, November 14, 2022 and Present at Upcoming Conferences
Investor call and webcast scheduled for Monday, November 14 at 8:00 a.m. EST Roivant will present at investor conferences in November BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that it
Read more →ROIV▲ +7.1%on this news
Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn In animal studies, deep IgG lowering similar to batoclimab with no or minimal impact on albumin and low-density lipoprotein (LDL) was observed. Plan to submit I
Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn NEW YORK, September 28, 2022 - Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced a new anti-FcRn, IMVT-1
Read more →ROIVRoivant to Participate in September Investor Events
Three healthcare investor conferences in September across Boston, New York and London Roivant Investor Day will take place virtually on September 28th starting at 11 a.m. EDT BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Roivant Scienc
Read more →ROIVRoivant Sciences Reports Financial Results for the First Quarter Ended
Roivant Sciences Reports Financial Results for the First Quarter Ended June 30, 2022 and Provides Business Update BASEL, Switzerland, LONDON, NEW YORK and BOSTON, August 15, 2022 Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to impr
Read more →ROIVRoivant Sciences to Report Financial Results for the Quarter Ended June 30, 2022 on Monday, August 15, 2022
Investor call and webcast scheduled for Monday, August 15 at 8:00 a.m. EDT Roivant will host an investor day on Wednesday, September 28 at 11:00 a.m. EDT BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV), a
Read more →ROIVRoivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
Brepocitinib is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1; in all five placebo-controlled studies completed to date, oral brepocitinib generated statistically significant and clinically meaningful results Priovant is developing brepocitinib in severe
Read more →ROIVRoivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended
Roivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 and Provides Business Update LONDON, NEW YORK and BOSTON, June 28, 2022 Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving
Read more →ROIV▲ +7.9%on this news
Roivant Sciences to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 on Tuesday, June 28, 2022
Investor call and webcast scheduled for Tuesday, June 28 at 8:00 a.m. EDT BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 15, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV), a biopharmaceutical company dedicated to improving the delivery of healthcare to pa
Read more →ROIV▲ +7.1%on this news
FDA Approves Dermavant s VTAMA (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years - EFFICACY: In the pivotal Phase 3
FDA Approves Dermavant s VTAMA (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years - EFFICACY: In the pivotal Phase 3 clinical trial program, VTAMA cream met all primary and se
Read more →ROIVRoivant to Present at Upcoming Investor Conferences
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) will participate in four upcoming healthcare investor conferences: UBS Global Healthcare Conference in New York City on Monday, May 23 at 9:15 a.m. EDT. CEO Ma
Read more →ROIVRoivant Appoints Chief Development Officer and Announces Multiple Collaborations in Targeted Protein Degradation
Dr. Srini Ramanathan has over 20 years of experience in drug development and joins Roivant from Horizon Therapeutics where he built scientific R&D capabilities and teams to advance the company’s preclinical and clinical portfolio In addition to internal pipeline programs, Roivan
Read more →ROIVForward-looking statements This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws
Immunovant R&D Day Enabling normal lives for people with autoimmune disease March 30, 2022 Exhibit 99.1 Forward-looking statements This presentation contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Refor
Read more →ROIVRoivant to Present at Targeted Protein Degradation Conference
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, March 11, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that its CEO Matt Gline will present at Guggenheim’s Targeted Protein Degradation Day on Wednesday, March 16, 2022 at 1:15 p.m. ET. A live we
Read more →ROIVGenevant Sciences and Arbutus Biopharma File Patent Infringement Lawsuit Against Moderna Conference call today at 8:00am ET VANCOUVER, BRITISH COLUMBIA, CAMBRIDGE, MASSACHUSETTS
Genevant Sciences and Arbutus Biopharma File Patent Infringement Lawsuit Against Moderna VANCOUVER, BRITISH COLUMBIA, CAMBRIDGE, MASSACHUSETTS, AND BASEL, SWITZERLAND, February 28, 2022 Genevant Sciences, a leading nucleic acid delivery company, and Arbutus Biopharma Corporatio
Read more →ROIV▲ +5.1%on this news
Roivant Sciences Reports Financial Results for the Quarter Ended
Roivant Sciences Reports Financial Results for the Quarter Ended December 31, 2021 and Provides Business Update BASEL, Switzerland, LONDON, NEW YORK and BOSTON, February 14, 2022 Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to impr
Read more →ROIVRoivant to Report Financial Results for the Quarter Ended December 31, 2021 on Monday, February 14, 2022
Quarterly investor call and webcast scheduled for Monday, February 14 at 8:00 a.m. ET Roivant will also present at the SVB Leerink Global Healthcare Conference in February, and the Truist AI Symposium and Cowen Healthcare Conference in March BASEL, Switzerland and LONDON and NE
Read more →ROIV▼ -6.5%on this news
Roivant Licenses Splicing Modulator and Announces Upcoming Presentation at 40th Annual J.P. Morgan Healthcare Conference
Roivant will develop RVT-2001 for the treatment of transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes Roivant JPM presentation scheduled for Monday, January 10, at 2:15 p.m. ET BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Jan. 05, 2022
Read more →ROIVRoivant to Report Financial Results for the Quarter Ended September 30, 2021 on Monday, November 15, 2021
Quarterly investor call and webcast scheduled on Monday, November 15th at 8:00am ET Roivant will also present at the Jefferies London Healthcare and Evercore ISI HealthCONx investor conferences in November BASEL, Switzerland, LONDON, NEW YORK and BOSTON, Nov. 08, 2021 (GLOBE NE
Read more →ROIVRoivant Sciences Announces Close of Business Combination with Montes Archimedes Acquisition Corp. and Concurrent PIPE Financing - Roivant will begin trading on Nasdaq under the ticker ROIV later today - R&D Day presentat
Roivant Sciences Announces Close of Business Combination with Montes Archimedes Acquisition Corp. and Concurrent PIPE Financing BASEL, Switzerland, LONDON, NEW YORK, and BOSTON, October 1, 2021 Roivant Sciences, a biopharmaceutical company dedicated to improving the delivery of
Read more →ROIVStatement of Limitations (1/2) The following is a series of presentations (the "Presentation") prepared by Roivant Sciences Ltd. and certain of its subsidiaries and affiliates (the "Company"). This Presentation is only f
Roivant R&D Day September 28, 2021 Statement of Limitations (1/2) The following is a series of presentations (the "Presentation") prepared by Roivant Sciences Ltd. and certain of its subsidiaries and affiliates (the "Company"). This Presentation is only for its intended investo
Read more →ROIVRoivant Sciences Reports First Fiscal Quarter 2021 Financial Results and Provides Business Update Roivant on track to close business combination with Montes Archimedes Acquisition Corp. ( MAAC ) and concurrent PIPE finan
Roivant Sciences Reports First Fiscal Quarter 2021 Financial Results and Provides Business Update BASEL, Switzerland, LONDON and NEW YORK, September 21, 2021 Roivant Sciences Ltd. ( Roivant or the Company ), a next-generation biopharmaceutical company dedicated to improving the
Read more →ROIVRoivant Acquires SB742457 From GlaxoSmithKline
-Roivant intends to commence Phase 3 clinical trials in Alzheimer's disease in 2015- -Development led by the developer of Alzheimer's medicine, Aricept- HAMILTON, Bermuda, Dec. 23, 2014 (GLOBE NEWSWIRE) -- Roivant Neurosciences Ltd. ("Roivant"), a biopharmaceutical company dedi
Read more →Competitive Position
How ROIV ranks across every disease it competes inCompetitive Position is a premium feature
See how ROIV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial